Bibliography
- American Cancer Society. Statistics for 2008. Available from: www.cancer.org/docroot/STT
- Saif MW. Pancreatic cancer: are we moving forward yet? Highlights from the Gastrointestinal Cancers Symposium; 20th January 2007; Orlando, FL, USA. JOP 2007;8(2):166-76
- Li J, Saif MW. Advancements in the management of pancreatic cancer. JOP 2009;10(2):109-17
- Blaszkowsky L. Treatment of advanced and metastatic pancreatic cancer [review]. Front Biosci 1998;3:E214-25
- Burris HA III, Moore MJ, Andersen J, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
- Louvet C, Labianca R, Hammel P, Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23(15):3509-16
- Heinemann V, Labianca R, Hinke A, Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007;18(10):1652-9
- Heinemann V, Boeck S, Hinke A, Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008;8:82
- Poplin E, Levy DE, Berlin J, Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine + oxaliplatin(GEMOX) in patients with advanced pancreatic cancer (E6201). 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18S):LBA4004
- Airoldi M, Cattel L, Passera R, Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. Pancreas 2006;32(1):44-50
- Saif MW. Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the 44th ASCO Annual Meeting; Chicago, IL, USA; 30 May – 3 June 2008. JOP 2008;9(4):403-7
- Moore MJ, Goldstein D, Hamm J, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6
- Valle JW, Wasan HS, Palmer DD, Gemcitabine with or without cisplatin in patients (pts) with advanced or metastatic biliary tract cancer (ABC): results of a multicenter, randomized phase III trial (the UK ABC-02 trial). J Clin Oncol 2009;27:15s(Suppl; Abstract 4503)